REMEDY : BNSSG referral pathways & Joint Formulary

BNSSG Paediatric Joint Formulary
Home > Formulary : Paediatric > Recent Decisions > 2022 >

Decisions 13th September 2022

Decisions 13th September 2022

At the meeting on the 13th September, the following decisions were agreed


New Drug Requests


Tretinoin 0.025% / Clindamycin 1% Gel (TLS Green)

  • For acne

  • Tretinoin/Erythromycin removed from the Formulary

 Synalar® (fluocinolone ointment 0.025%) ointment/cream (TLS Blue)

  • For severe inflammatory skin disorders such as eczema and psoriasis

  • Synalar gel (already on formulary) TLS changed from green to blue inline with other formulations of Synalar.

Melatonin (TLS Red)

  • Off-label for use on PICU and HDU (during hospital stay only) to aid onset of sleep in patients with neurodevelopmental disorders/ASD and other conditions e.g. bone marrow transplant and renal patients who are suffering from sleep cycle disorder following prolonged stays and who have not responded to standard sleep hygiene measures.


Decision Pending 

Melatonin (Adults and Paediatrics)

  • Off-label use for sleep disorder in adult and paediatric patients with any of:

    • Attention Deficit Hyperactivity Disorder (ADHD)

    • Autism Spectrum Disorder (ASD)

    • Learning Disabilities (LD)